---
title: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. Reply
date: '2023-08-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37530836/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20230802180824&v=2.17.9.post6+86293ac
source: N Engl J Med
description: No ...
disable_comments: true
---
No ...